ENTITY
Sciclone Pharmaceuticals

Sciclone Pharmaceuticals (6600 HK)

104
Analysis
Health Care • China
SciClone Pharmaceuticals (Holdings) Limited operates as a biopharmaceutical company. The Company develops produces and sells oncology drug, infectious diseases drugs and other products. SciClone Pharmaceuticals (Holdings) markets its products throughout China.
more
•22 Feb 2021 15:47

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

SciClone has set the terms for its IPO, where it plans to issue approx. 116m shares at an indicative IPO price range of HK$17.2-18.8 per share to...

Share
bullish•Tencent
•21 Feb 2021 10:22

ECM Weekly (21 February 2021) - Tencent Lock-Up Expiry, SciClone Pharma, Joinn Lab, Bairong, Betta

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
•19 Feb 2021 15:34

SciClone Pharmaceuticals IPO: Valuation Insights

SciClone has launched its IPO to raise net proceeds of $252m, at the mid-point of the price range. We recommend a pass as our concerns on the...

Logo
1k Views
Share
•19 Feb 2021 14:01

SciClone (čµ›ē”ŸčÆäøš) IPO: A Mediocre Deal

We think the cornerstone is mediocre and the deal is fairly valued. The recent reference deal of its close peer, Simcere, has done poorly. We will...

Logo
646 Views
Share
•17 Feb 2021 05:31

JOINN Laboratories IPO: Attractive Valuation; Overseas Expansion Should Open Up Room for LT Growth

Joinn Laboratories, the pioneer of commercial GLP laboratories in China has filed for a secondary listing to list its shares on the Hong Kong Stock...

Share
x